Tech firm Kromek remains loss-making despite record revenues

Kromek CEO Arnab Basu with detection technology

North East technology company Kromek has reported record results but remains loss-making and has lined up new funding from one of its main shareholders.

The County Durham firm makes radiation and bio-detection equipment and has made headlines for the use of its products at high profile diplomatic events, as well as on the battlefield in Ukraine. It has often been named as one of the country’s most innovative companies due to its high number of patents, but it has struggled to fully commercialise its technology and is yet to declare a profit since being founded as a spin-out from Durham University research in 2003.

In new results for year ending April 30, Kromek said its revenue increased 12% to £19.4m and it achieved positive adjusted Ebitda of £3.1m. But it remained loss-making, though the loss before was more than halved from £7.3m last year to £3.5m. Its cash position worsened to stand at £500,000 but it also announced a new £4.9m loan from Polymer N2, an investment vehicle controlled by Dr Graeme Speirs, an existing shareholder who already provides finance to the firm.

Kromek CEO Dr Arnab Basu said: "This has been a pivotal 12 months for Kromek where we recorded a third consecutive year of revenue growth and delivered on all our KPIs. We achieved record revenues, more than halved our losses and our positive adjusted Ebitda exceeded market expectations.

“We have actively enhanced our operational efficiencies and seen excellent progress in both advanced imaging and CBRN detection where demand remains strong across both market segments. We expect to be broadly cash neutral in H1 and are comfortable that we have sufficient capital to deliver further growth in 2025.

"Looking ahead, we anticipate demand for our CBRN products will continue to be driven by global geopolitical insecurity and the persistence of nuclear threats…Consequently, Kromek is well positioned to deliver future growth and value for shareholders."

Kromek said it had seen significant progress in its medical imaging operations, including a $2.1m order in the US from an existing customer. It added that global insecurity continued to drive demand in its nuclear security products and in biological threat detection.